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ABSTRACT
During osteoclast differentiation and resorption, both NF-kappaB and Notch signalling are activated. This study defines the mechanism about the influence of NFkappaB on Notch. To this end, IkappaBalphaM and Wild-type-IkappaBalpha were transfected into RAW 264.7 cells. The number of cells that differentiated into osteoclasts was quantified. The resorption area was measured. NF-kappaB transcriptional activity was determined by EMSA. Hes1, DC-STAMP and MMP-9 mRNA expression levels were determined by RT-PCR. Hes1 protein expression was determined by western blots. ChIP was used to study binding of IkappaBalpha to the Hes1 promoter. NF-kappaB inactivation inhibited the differentiation and resorption ability of osteoclasts. Compared with Wild-type cells, NF-kappaB inactivation resulted in an up-regulation of Hes1 expression, and a down-regulation of DC-STAMP and MMP-9 expression. Moreover, in response to RANKL, NF-kappaB inactivation resulted in a down-regulation of DC-STAMP and MMP-9 expression compared with Wild-type cells. The Hes1 promoter was detected by ChIP using IkappaBalpha antibody. In conclusion, our data suggest IkappaBalpha regulates Hes1-mediated activity in osteoclast differentiation and resorption, which support a cross-talk between NF-kappaB and Notch in osteoclast activity.
INTRODUCTION
The development and continuous remodeling of the skeleton demand a tightly regulated balance between boneformation and bone-resorption. Although many aspects of the resorptive processes remain elusive, a general understanding is that the osteoclast is the pivotal cell in the degradation of the bone matrix (1) . Osteoclasts are derived from hematopoietic myeloid precursors of the monocyte/macrophage lineage and under the control of systemic and local factors produced by supporting cells such as osteoblasts and bone marrow stromal cells. Among these factors, RANKL is the key cytokine that stimulates osteoclast differentitation both in vitro and in vivo (2-4). RANK, the receptor of RANKL, is expressed on the surface of osteoclast progenitor cells. When RANK binds to its ligand, intracellular signals including NF-kappaB are induced, leading to osteoclast formation (5).
NF-kappaB is a transcriptional factor family. It consists of c-Rel, p50, p52, p65 and RelB, which can form various homodimers or heterodimers through a highly conserved N-terminal Rel homology domain. In the cytoplasm of quiescent cells, the dimers bind inhibitory molecules of the IkappaB family. Cell activation by various stimuli including RANKL results in serine phosphorylation and degradation of IkappaB. Subsequently, NF-kappaB dimers translocate into the nucleus and regulate downstream gene expressions (6) (7) (8) . Moreover, IkappaBalpha can also shuttle between nucleus and cytoplasm (9, 10), which adds complexity to the system. Although nucleocytoplasmic shuttling of IkappaBalpha is important for the termination of NF-kappaB signaling, its physiological effect has not been completely understood. It is possible that IkappaBalpha may have an additional unidentified function. It has been recently demonstrated that TNF-alpha stimulation led to the release of IkappaBalpha and upregulation of Notch-dependent Hes1 (Hairy and enhancer of split) gene expression in fibroblast 3T3 cells and human embryonic kidney 293T cells (11) . Hes1 encodes a basic helix-loop-helix transcription factor that functions as a classical effector of the Notch signaling pathway (12) .
Recent findings suggest an important role of Notch in cell-fate determination of haemotopoietic progenitor cells (13) . In canonical Notch signaling, binding of transmembrane Notch receptors (N1-N4) by Jagged or Delta ligands results in gamma-secretase-mediated cleavage and release of the Notch intracellular domain, its nuclear translocation and association with the transcriptionalactivator Mastermind, and DNA-binding protein, CSL/RBP-J (14) . This heterotrimeric complex induces the expression of Notch target genes, such as Hes1 (12) .
As cells are frequently exposed to simultaneous activation of different signaling pathway, a fundamental question is, how different transduction pathways integrate into the final message resulting in a biological response? The aim of the present study was to investigate the possible coordination between the NF-kappaB and the Notch signaling pathway in osteoclast formation and function. Here, we present evidence that the regulation of Hes1 by NF-kappaB occurs via a mechanism that is dependent on the release of IkappaBalpha from the Hes1 promoter in RANKL-induced osteoclast activity. It has important implications for future therapeutic approaches directed against these signaling pathways involved in bone diseases. 
MATERIALS AND METHODS
3
Osteoclast formation assays
Mutant and Wild-type cells were plated at a density of 1.3×10 4 /cm 2 into chamber slides (Nalge Nunc International, Rochester, New York, USA) in the presence of RANKL (100ng/ml). The medium was changed every 2 days. After 5 days of culture, the cells were fixed and stained using the TRAP staining kit (Sigma-Aldrich, St Louis, MO, USA) according to the manufacturer's instructions. TRAP-positive cells with more than three nuclei were considered to be osteoclast-like cells. The number of osteoclast-like cells was counted under a light microscope.
Resorption assays
Mutant and Wild-type cells were plated at a density of 1.3×10 4 /cm 2 onto Osteoclast Activity Assay Substrate (Osteogenic Core Technologies, Chunan, Choongnam, Korea) and treated with 100 ng/ml RANKL. Medium was changed every 2 days. After 10 days of culture, the plates were washed to remove the cells. The resorption areas on the plates were photographed with a digital camera attached to the microscope and analyzed by the Image Analysis System (Leica, Solms, Germany).
Real-time PCR
Mutant and Wild-type cells were plated at a density of 1.3×10 4 /cm 2 in 60 mm tissue culture dishes in the presence of RANKL (100 ng/ml). After 24 h of incubation, total RNA was extracted using Absolutely RNA Miniprep kit (Stratagene, CA, USA) according to the manufacturer's instructions. cDNA was synthesized with superscript reverse transcriptase (Invitrogen, Nelson, UK), followed by quantitative real time PCR with gene specific primers. Hes1 primers (5-ACCCAGCCAGTGTCAACA-3 and 5-CATTGATAGGCTTTGATGACTTTCTG-3), DC-STAMP primers (5-TTGCCGCTGTGGACTATCTG -3 and 5-GAATGCAGCTCGGTTCAAAC -3), and MMP-9 primers (5-TTCCCCAAAGACCTGAAAACC-3 and 5-GCCCGGGTGTAACCATAGC-3) were designed using Primer Express 2.0 (Applied Biosystems, Foster City, CA, USA). Relative quantities of mRNA expression were analysed using Quantitative RT-PCR (Bio-Rad, CA, USA) in the presence of SYBR green (Applied Biosystems, Foster City, CA, USA). For the normalization of each sample, the expression level of the gene was divided by that of beta-actin.
Cell extracts preparation and Western blot analysis
Mutant and Wild-type cells were washed twice with ice-cold PBS, scraped and collected by centrifugation. Cell pellets were lysed with cytoplasmic lysis buffer. The tubes were gently vortexed for 15 min. Nuclei were collected by centrifugation at 8000 g for 15 min, and the supernatants were stored at -80 °C. To obtain nuclear protein extracts, the pellets were resuspended in lysis buffer, and gently shaken for 30 min at 4 °C, followed by centrifugation at 13,000 g for 15 min. Protein concentrations of the extracts were determined by using the Bio-Rad protein agent (Bio-Rad, Muchen, Germany). Fifty micrograms of total protein was resolved on a 10% SDS-PAGE gel, transferred to a nitrocellulose membrane, and probed with primary antibody Phospho-NF-kappaB p65 (Ser536) (Cell Signaling Technologies, Beverly, MA, USA) and Hes1 (Santa Cruz Biotech, Santa Cruz, CA, USA). Specific binding was detected using a secondary antibody coupled to horseradish peroxidase and the Lumi-light Plus Western blot substrate (Roche diagnostics GmbH, Munniheim, Germany). After detection, blots were stripped and reprobed with primary antibody beta-actin (Santa Cruz Biotech, Santa Cruz, CA, USA).
The bands were quantified by Quantity One software (Bio-Rad, CA, USA).
Electrophoretic mobility shift assay (EMSA)
Electrophoretic mobility shift assay (EMSA) was performed using NF-kappaB oligonucleotide probe (5-AGTTGAGGGGACTTTCCCAGGC-3) end-labeled with [gamma-32 P]. Nuclear protein (2 µg) was pre-incubated in binding buffer, consisting of 10 mM Tris-Cl, pH 7.5, 1 mM MgCl 2 , 50 mM NaCl, 0.5 mM EDTA, 0.5 mM DTT, 4% glycerol, and 0.05 µg/ml of poly (dI-dC) (deoxyinosinic deoxycytidylic acid) (Amersham Biosciences) for 15 min at room temperature. After addition of the 2 µl [gamma-
32 P]-labeled oligonuleotide probe, the incubation was continued for 30 min at room temperature. The reaction was terminated by adding 1 µl gel loading buffer, and the mixture was subjected to non-denaturing 4% polyacrylamide gel electrophoresis in 0.5 × TBE buffer. The gel was exposed to X-ray film for 1 h to overnight at -80 °C with an intensifying screen and scanned. The bands were quantified by Quantity One software..
Chromatin immunoprecipitation (ChIP)
Approximately 2×10 6 RAW 264.7 cells with or without RANKL stimulation were cross-linked in the presence of 1% formaldehyde for 15 min at room temperature. Cross-linking was stopped on addition of glycine to a final concentration of 125 mM for 5 min at room temperature. Cells were washed twice with cold 1× PBS, scraped, and centrifuged at 100g for 5 min. Cell pellets were resuspended in 400 µl lysis buffer (5 mM Pipes [KOH], pH 8.0, 85 mM KCl, 0.5% NP40, containing complete protease inhibitors) and incubated on ice for 10 min. Nuclei were pelleted in a microcentrifuge at 1500g for 5 min at 4 °C. The nuclei preparations were resuspended in 200 µl nuclear lysis buffer (50 mM Tris, pH8, 10 mM EDTA, pH 8, 1% SDS, complete protease inhibitors) and incubated on ice for 10 min. While on ice, samples were sonicated with 6×20s bursts using a branson sonifier. Debris was cleared by centrifugation at 15,800g for 5 min. The supernatant was transferred to a new tube and diluted 5-fold in chromatin immunoprecipitation (ChIP) dilution buffer (0.01% SDS, 1.1% TritionX 100, 1.2 mM EDTA, 16.7 mM Tris, pH8, 167 mM NaCl including complete protease inhibitors). To reduce nonspecific backgroud, the samples were precleaned with 40 µl protein G sepharose and 20 µg salmon sperm DNA. Twenty percent of the samples were kept as a total input control. Anti-IkappaBalpha antibody or rabbit Ig (10 µg/ml) was used for immunoprecipitation, prearmed with 20 µl protein G sepharose /20 µg salmon sperm DNA slurry overnight at 4 °C. Beads were washed three times in low salt buffer (0.1% SDS, 1.0% TritionX 100, 2 mM EDTA, 20 mM Tris, pH8, 150 mM NaCl) for 10 min at 4°C and three times with high salt buffer (0.1% SDS, 1.0% TritionX 100, 2 mM EDTA, 20 mM Tris, pH8, 500 mM NaCl). Cross-linkage was reversed by heating at 65°C, followed by treatment with 40 µg/ml proteinase K at 45 °C for 60min. DNA was recovered by phenol-chlorophormethanol precipitation and used as a template for PCR to amplify the region including the IkappaBalpha site in the Hes1 promoter. Primers for input and sample preparations: Forward 5'-TTCCTCCCATTGGCTGAAAG-3'; Reverse 5'-GTGATCGGTAGCACTATTCC-3' (195bp, NC000082). PCR amplification was achieved at 94°C/30s; 58°C/30s and 72°C/30s for 25 cycles. The PCR products were electrophoresed on a 1% agrose gel and stained with ethidium bromide.
Data analysis
Data were expressed as mean +/-SD. Statistical differences were determined using ANOVA or student's t test for repeated measures; p <0.05 was considered to be significant.
RESULTS
Stable expression of IkappaBalphaM in RAW 264.7 cells
To profile the extent of IkappaBalphaM expression in RAW 264.7 cells used for the present studies, we selected several subclones stably expressing exogenous IkappaBalphaM (Mutant cells), as well as several RAW 264.7 subclones stably expressing the IkappaBalpha gene (Wild-type cells), transfected with IkappaBalpha vectors, as a control. NF-kappaB DNA binding activity was detected with EMSA. First, the NFkappaB probe specificity was tested with competitive analysis ( Figure 1A ). Shift bands decreased with increasing amount of unlabelled NF-kappaB while no change of shift band with addition of noncompetitive SP1 probe. EMSA results show that RANKL increased amounts of nuclear complex protein of NF-kappaB in Wild-type cells compared with Mutant cells (Figure 1B, 1C) . A 2.1-fold decrease in the level of p65 nulcear protein was observed in Mutant cells ( Figure 1D, 1E) , whereas positive, but relatively higer level, of p65 nulcear protein was expressed in control cells (Wild-type cells). EMSA and Western blot results demonstrated that NF-kappaB signaling has been inactivated after IkappaBalphaM vector transfected into RAW 264.7 cells.
NF-kappaB mediates RANKL-induced differentiation and resorption
Osteoclasts are multinucleated cells with TRAPpositive staining. TRAP staining showed that osteoclast number increased after treatment with RANKL for 5 days. Osteoclast formation was impaired in Mutant cells compared with Wild-type cells (Figure 2A ). These results clearly indicate a role of NF-kappaB in osteoclast differentiation.
Bone resorption assays were subsequently carried out for understanding whether the osteoclast-like cells induced by RANKL are active. As shown in the Figure 2C , some pit formation was detectable in the cultures of Mutant cells. However, the number and the size of pits formed were further augmented in the cultures of Wild-type cells when these cells were incubated at the same conditions ( Figure 2B ). Resorption assay results showed the resorption activity of RAW 264.7 cells induced by RANKL was significantly inhibited after NF-kappaB inactivation ( Figure 2D ). 
NF-kappaB inactivation down-regulates MMP-9 and DC-STAMP expression
MMP-9 and DC-STAMP are target genes of NFkappaB signaling. In the absence of stimuli, RT-PCR results demonstrated that MMP-9 and DC-STAMP expression was down-regulated after NF-kappaB inactivation ( Figure 2E ). In response to RANKL, RT-PCR results demonstrated that MMP-9 and DC-STAMP expression was down-regulated after NF-kappaB inactivation ( Figure 2F ).
NF-kappaB inactivation up-regulates Notchdependent Hes1 gene expression
Expression of NF-kappaB M in RAW 264.7 cells results in NF-kappaB inactivation. In the absence of stimuli, we detected higher levels of Hes1 mRNA and protein in Mutant cells compared with Wild-type cells ( Figure 3A, 3B and 3C) . Furthermore, Hes1 mRNA and protein expression was up-regulated after RANKL treatment in Wild-type cells ( Figure  3A, 3D and 3E) . 
NF-kappaB inactivation exerts a positive effect on the transcriptional activation of the Hes1 promoter
As IkappaBalpha modulates the Hes1 gene expression, we hypothesized that the IkappaBalpha fraction interacts with the repressor elements was directly responsible for Hes1 expression. To test this, ChIP assays were performed to investigate whether IkappaBalpha protein was combined to the promoter region of this gene. Hes1 promoter was detected from chromatin precipitated with IkappaBalpha antibody, thus indicating that this promoter is indeed able to bind IkappaBalpha. As a control, Hes1 promoter could not be amplified from precipitates with nonrelevant immunoglobulins or with RANKL treatment (Figure 4A, 4B ). These observations strongly support that chromatin-associated IkappaBalpha is involved in the recruitment of specific repression complexes in the noninduced state, and RANKL regulates Hes1 transcriptional activation by modulating the association of IkappaBalpha with the Hes1 promoter.
DISCUSSION
It is well established that RANKL regulates osteoclast differentiation and resorption mainly via NFkappaB signaling (15) . Our results further confirmed that NF-kappaB signaling is involved in RANKL-induced osteoclast differentiation and resorption. In these processes, NF-kappaB regulates Notch signaling. This is the first study reporting that NF-kappaB influences Notch via the binding of Hes1 promoter in osteoclast activity.
It is generally accepted that NF-kappaB plays an important role in osteoclast formation. TRAP staining is an often-used method to examine osteoclast formation, and TRAP-positive multinucleated cells including osteoclasts or osteoclast-like cells (16, 17) . In this study, TRAPpositive multinucleated cells were observed after RANKLinduced NF-kappaB activation, whereas the number of RANKL-induced TRAP-positive multinucleated cells was significantly decreased, after NF-kappaB inactivation by IkappaBalphaM transfection. Studies have demonstrated that RANKL modulates the DC-STAMP expression in osteoclast formation (18) and NF-kappaB binds directly to the DC-STAMP promoter (19) . Moreover, MMP-9 plays a crucial role in bone matrix degradation (20) and MMP-9 expression is modulated by RANKL through regulation of NF-kappaB followed by NFAT activation (18) . Our study shows that NF-kappaB inactivation results in decreased DC-STAMP and MMP-9 expression as well as bone resorption ability of osteoclasts, thus providing further evidence that NF-kappaB plays a role in osteoclast formation and resorption.
Notch and NF-kappaB pathways are involved in the regulation of gene expression and cellular events in many different systems. The effect of each pathway in inhibiting or promoting differentiation is controversial and it could depend on the cellular context (21) (22) (23) . Furthermore, Notch and NF-kappaB exert antagonistic or synergistic effects in different system (24, 25) . However, the results of this study strongly support the view that NFkappaB promotes osteoclast differentiation in response to RANKL stimulation. Meanwhile, Notch-dependent Hes1 is up-regulated and the Notch pathway is activated. Our results demonstrated that recruitment of IkappaBalpha to the Hes1 promoter mediated the process in which NF-kappaB regulates Notch activity. RANKL treatment results in the release of Chromatin-associated IkappaBalpha from the Hes1 promoter, coinciding with the transcriptional activation of this gene. This finding suggested a cross-talk between the NFkappaB and Notch pathways exists in osteoclasts. Such crosstalk may contribute to additional complexity in the regulation of cell behavior. In the immune system, NF-kappaB mediates Jagged1 expression, which can initiate signaling downstream of Notch (26). However, in the 32D myeloid progenitor system, NF-kappaB inhibits Notch-dependent gene Hes1 (27) . On the other hand, many cellular processes have been reported in which activation of Notch signaling correlates with the inhibition of the NF-kappaB pathway. Whether Notch activation enhances or inhibits the activity of NF-kappaB in RAW 264.7 cells in response to RANKL awaits confirmation in our future study.
In conclusion, this study showed that recruitment of IkappaBalpha to the Hes1 promoter was associated with transcriptional repression, and this mechanism was involved in the osteoclast differentiation and resorption. Our findings may provide important clues to understanding the coordination of Notch and NF-kappaB pathways in controlling osteoclast cellular events, and to modulating the state of bone metabolic diseases.
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